DIFFERENTIAL SCAVENGING OF APOPTOTIC CELLS AND BACTERIA (2017) Kronke G Conference contribution ABATACEPT BUT NOT TNF INHIBITORS BLOCK AUTOANTIBODY-MEDIATED CYTOKINE PRODUCTION BY MONOCYTES (2017) Bozec A, Luo Y, Engdahl C, Figueiredo C, Bang H, Schett G Conference contribution APREMILAST TREATMENT AND LONG-TERM (UP TO 156 WEEKS) IMPROVEMENTS IN DACTYLITIS AND ENTHESITIS IN PATIENTS WITH PSORIATIC ARTHRITIS: ANALYSIS OF A LARGE DATABASE OF THE PHASE III CLINICAL DEVELOPMENT PROGRAM (2017) Gladman DD, Kavanaugh A, Gomez-Reino JJ, Wollenhaupt J, Cutolo M, Schett G, Lespessailles E, et al. Conference contribution DURABILITY OF APREMILAST RESPONSE IN PATIENTS WITH PSORIATIC ARTHRITIS: LONG-TERM (208-WEEK) RESULTS FROM THE PALACE 1 TRIAL (2017) Kavanaugh A, Gladman DD, Gomez-Reino JJ, Hall S, Lespessailles E, Mease PJ, Schett G, et al. Conference contribution DIFFUSING CAPACITY AND CLINICAL CHARACTERISTICS OF PATIENTS WITH SYSTEMIC SCLEROSIS - DATA FROM THE GERMAN NETWORK FOR SYSTEMIC SCLEROSIS (2017) Moinzadeh P, Blank N, Siegert E, Henes J, Worm M, Sunderkoetter C, Schmalzing M, et al. Conference contribution CORTICAL BONE LOSS IS AN EARLY FEATURE OF AXIAL SPONDYLOARTHRITIS (2017) Haschka J, Neumann A, Kleyer A, Schuster L, Englbrecht M, Figueiredo CP, Muschitz C, et al. Conference contribution PREVALENCE AND CHARACTERISTICS OF SPONDYLOARTHRITIS ACCORDING TO ASAS CRITERIA IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE - RESULTS FROM THE SPICE COHORT (2017) Haschka J, Hirschmann S, Kleyer A, Englbrecht M, Zimmermann J, Faustini F, Simon D, et al. Conference contribution IMPACT OF TOLL-LIKE RECEPTOR 9 IN INFLAMMATORY ARTHRITIS AND OSTEOCLASTOGENESIS (2017) Fischer A, Boehm C, Koenders M, Van Den Berg W, Rothe T, Krönke G, Dudziak D, Steiner G Conference contribution INCREASE OF CORTICAL MICRO-CHANNELS (COMICS) AS A NEW FEATURE OF STRUCTURAL DAMAGE IN PAIENTS WITH RHEUMATOID ARTHRITIS (2017) Werner D, Simon D, Englbrecht M, Stemmler F, Berlin A, Haschka J, Renner N, et al. Conference contribution ELEVATED MULTI-BIOMARKER DISEASE ACTIVITY (MBDA) PREDICTS RELAPSES IN RA PATIENTS IN SUSTAINED REMISSION TAPERING TUMOUR NECROSIS FACTOR INHIBITOR THERAPY-RESULTS FROM THE RANDOMIZED CONTROLLED RETRO STUDY (2017) Rech J, Hagen M, Englbrecht M, Haschka J, Reiser M, Kleyer A, Hueber A, et al. Conference contribution